Literature DB >> 1735611

Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo.

F Buchegger1, A Pèlegrin, N Hardman, C Heusser, J Lukas, W Dolci, J P Mach.   

Abstract

Mouse-human chimeric monoclonal antibodies (MAbs) of 3 different human IgG sub-classes directed against carcinoembryonic antigen (CEA) have been produced in SP-0 cells transfected with genomic chimeric DNA. F(ab')2 fragments were obtained by pepsin digestion of the purified chimeric MAbs of human IgG1, IgG2 and IgG4 sub-class and of parental mouse MAb IgG1. The 4 F(ab')2 fragments exhibit similar molecular weight by SDS-PAGE. They were labelled with 125I or 131I and high binding (80 to 87%) to purified unsolubilized CEA was observed. In vivo, double labelling experiments indicate that the longest biological half-life and the highest tumour-localization capacity is obtained with F(ab')2 from chimeric MAb of human IgG2 sub-class, whereas F(ab')2 from chimeric MAb IgG4 give very low values for these 2 parameters. F(ab')2 from chimeric MAb IgG1 and from parental mouse MAb yield intermediate results in vivo. Our findings should help to select the appropriate human IgG sub-class to produce chimeric or reshaped MAb F(ab')2 to be used for tumour detection by immunoscintigraphy and for radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735611     DOI: 10.1002/ijc.2910500316

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.

Authors:  Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

2.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

3.  Biological and pharmacokinetic properties of a novel immunoglobulin-CD4 fusion protein.

Authors:  J B Lyczak; S L Morrison
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 4.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

5.  Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.

Authors:  G Westera; T Rülicke; A Smith; S Duewell
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

6.  Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Authors:  J L Casey; D J King; L C Chaplin; A M Haines; R B Pedley; A Mountain; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.

Authors:  C A Vogel; A Bischof-Delaloye; J P Mach; A Pèlegrin; N Hardman; B Delaloye; F Buchegger
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  Development and characterization of chimeric anti-carcinoembryonic antigen monoclonal antibodies and their Fab fragments.

Authors:  T Kamigaki; H Ohyanagi; M Yamamoto; T Kaneda; T Goto; T Ohmura; K Yokoyama; Y Saitoh
Journal:  Jpn J Cancer Res       Date:  1994-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.